Skip to main content
Signal8

Vincerx Pharma, Inc. (VINC)

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.

Sector: Biotechnology

Industry: Biotechnology

Vincerx Pharma, Inc. logo

Vincerx Pharma, Inc.

OTC:VINCHealthcare
+0.00%$0.0150
CLOSED
Mkt Cap$79K
EV-
Float5.23M
O/S5.23M
VOL663 sh
$ Vol$10
RVOL0.50×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Vincerx Pharma, Inc. logoOTC:VINCClosed$0.0150+0.00%
Financials Summary
Revenue$0
Net Income-$30.07M
Total Assets$8.01M
Free Cash Flow-$26.13M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$2.72M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
2-year cumulative
1:20

Nasdaq bars a compliance period at 1:250

  1. 1:20Reverse split
    Jan 28, 202520 shares → 1
Balance Sheet Details
Assets$8.01M
Liabilities$5.28M
Accounts Receivable$1.04M
Accounts Payable$2.03M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSD
Period Ending2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$0$0$0$0$0
YoY Growth------
Cost of Revenue$1.09M$915K$939K$340K$173K$173K
Gross Profit-$1.09M-$915K-$939K-$340K-$173K-$173K
Gross Margin------
Research and Development$15.49M$28.06M$52.15M$40.08M$7.12M$0
Selling, General, and Administrative$15.98M$13.64M$18.95M$22.57M$3.6M$45K
Other$0$0$0$0$0$0
Total Operating Expenses$31.46M$41.69M$71.11M$62.66M$10.71M$45K
Operating Income (EBIT)-$31.46M-$42.61M-$68.72M-$62.66M-$10.71M-$45K
Operating Margin------
Interest Expense$0$0$0$0$8K$0
Interest Income$472K$1.25M$664K$0$54K$54K
Other Income (Expense)$1.39M$2.45M$5.74M$23.35M-$5.91M$0
Income Before Tax (EBT)-$30.07M-$40.16M-$62.98M-$39.31M-$16.62M-$45K
Income Tax Expense$0$0$0$0$0$0
Net Income-$30.07M-$40.16M-$65.37M-$39.31M-$16.62M-$54K
Net Income Margin------
Supplementary Data
EPS-5.75-6.84-10.86-8.30-11.67-0.03
Diluted EPS-5.75-6.84-10.86-8.30-11.67-0.03
Weighted Average OS5.23M5.87M5.80M4.74M1.42M1.43M
EBITDA-$31.46M-$39.24M-$62.05M-$38.97M-$15.83M$9K
EBITDA Margin------
Balance Sheet
PeriodFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSD
Period Ending2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Assets
Current Assets
Cash and Cash Equivalents$4.99M$12.78M$11.66M$111.46M$61.79M$685
Short-Term Investments$0$0$40.8M$0$0$0
Cash and Short-Term Investments$4.99M$12.78M$52.46M$111.46M$61.79M$685
Accounts Receivable$1.04M$1.04M$1.37M$0$0$0
Inventory$0$0$0$0$0$0
Other Current Assets$128K$856K$2M$200K$214K$106
Total Current Assets$6.41M$14.73M$55.96M$111.84M$63.11M$791
Long-Term Assets
Property, Plant & Equipment Net$0$2.33M$3.24M$4.18M$0$0
Goodwill$0$0$0$0$0$0
Intangible Assets$0$0$0$0$0$0
Long-Term Investments$1.59M$0$0$0$65.69M$1K
Deferred Tax Assets$0$0$0$0$0$0
Other Long-Term Assets$0$1.16M$81K$1.65M-$65.61M$0
Total Long-Term Assets$1.59M$3.48M$3.32M$5.83M$82K$1K
Other Assets$0$0$0$0$0-$791K
Total Assets$8.01M$18.22M$59.29M$117.68M$63.19M$1K
Liabilities
Current Liabilities
Accounts Payable$2.03M$2.5M$4.07M$2.02M$491K$35K
Short-Term Debt$0$0$0$0$0$0
Current Income Tax Payable$0$0$0$0$812$812
Current Unearned Revenue$0$0$0$4.71M$0$0
Other Current Liabilities$8K$191K$2.19M$1.73M$27.31M$9K
Total Current Liabilities$5.28M$5.61M$9.16M$13.92M$37.81M$44K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0
Other Long-Term Liabilities$0$50K$50K$0$0$0
Total Long-Term Liabilities$0$1.39M$2.46M$3.44M$491K$3K
Other Liabilities$0$0$0$0-$3.3M-$3.3M
Total Liabilities$5.28M$7M$11.62M$17.36M$5.5M$44K
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0
Common Stock$8K$2K$2K$2K$1K$1K
Retained Earnings-$189.19M-$159.11M-$118.95M-$55.97M-$16.66M-$45K
Comprehensive Income & Other$119K$8K-$26K-$21K$0-$1K
Other Stockholders' Equity$191.9M$170.33M$166.62M$156.29M$42.04M$0
Total Equity$2.72M$11.22M$47.67M$100.32M$25.38M-$44K
Minority Interest$0$0$0$0$0$0
Total Liabilities and Equity$8.01M$18.22M$59.29M$117.68M$30.88M$0
Supplementary Data
Total Debt$0$2.5M$3.44M$4.17M$0$0
Net Debt-$4.99M-$10.28M-$8.23M-$107.28M-$61.79M-$685
Cash Flow Statement
PeriodFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSD
Period Ending2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating Activities
Net Income-$30.07M-$40.16M-$65.37M-$39.31M-$10.38M-$54K
Depreciation & Amortization$1.09M$915K$939K$340K$20K$54K
Deferred Income Tax$0$0$0$0$0$0
Stock-Based Compensation$3.47M$3.56M$10.06M$23.31M$4.38M$1K
Changes in Working Capital:
  Accounts Receivable$0$328K$200K$0$0$0
  Inventory$0$0-$200K$0$0$0
  Accounts Payable-$468K-$1.57M$1.05M$1.53M$456K$35K
  Other Working Capital$290K-$2.95M-$2.07M$4.08M-$1.42M$0
Total Working Capital Change-$178K-$4.19M-$1.02M$5.61M-$959K$11K
Other Non-Cash Items-$438K-$583K-$4.21M-$23.36M$4.66M-$47K
Net Cash from Operating-$26.13M-$40.45M-$59.6M-$33.4M-$2.28M-$35K
Investing Activities
Capital Expenditures$0$0$0-$5.26M$0$0
Acquisitions$0$0$0$0$0$0
Purchases of Investments-$11.46M-$11.82M-$42.98M$0$0$0
Sales of Investments$11.68M$53.32M$2.4M$0$0$0
Other Investing Activities$0$0$0$0-$65.64M-$65.64M
Net Cash from Investing$212K$41.5M-$40.58M-$5.26M-$65.64M-$65.64M
Financing Activities
Debt Repaid------
Common Stock Issuance$17.87M$114K$280K$47.43M$0$0
Common Stock Repurchases$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0
Other Financing Activities$118K$114K$280K$41.02M$64.07M$66.46M
Net Cash from Financing$17.99M$114K$280K$88.45M$64.07M$66.46M
Forex Effect$135K-$40K$71K-$21K$65.64M$0
Net Change in Cash-$7.79M$1.12M-$99.83M$49.77M$61.79M$790K
Supplementary Data
Operating Cash Flow-$26.13M-$40.45M-$59.6M-$33.4M-$2.28M-$35K
Capital Expenditure$0$0$0-$5.26M$0$0
Free Cash Flow-$26.13M-$40.45M-$59.6M-$38.66M-$2.28M-$35K
Cash at Beginning$12.85M$11.73M$111.56M$61.79M-$35K-$825K
Cash at End$5.07M$12.85M$11.73M$111.56M$61.79M-$35K